BrainStorm Eyes New Phase III Trial For NurOwn In Mild ALS Following BLA Withdrawal

 
• By Sue Sutter
  
Line not crossed
NurOwn shows there is a line that FDA will not cross when it comes to regulatory flexibility. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Product Reviews

More from Pink Sheet